4basebio AG announced that agreed that the two members of the Management Board, Dr. Heikki Lanckriet and Mr. David Roth, will each resign from the Management Board of 4basebio AG with effect from December 30, 2020. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021. The Supervisory Board would like to thank Dr. Heikki Lanckriet and Mr. David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr. Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas.